Immunotherapy

Epicutaneous immunotherapy was superior to placebo in desensitizing toddlers to peanuts and in increasing the dose of peanuts that trigger allergic symptoms, according to a study published in The New England Journal of Medicine.

In this edition, tumor mutational burden linked to immunotherapy response; toripalimab regimen extends EFS in stage III NSCLC; phase 3 study designed for increasing trial diversity, and more.

DESTIN, Fla. — The history of immunology includes snake bites and cowpox, and is built on the work of scientists dating back more than 2,000 years, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

The combination of belzutifan and cabozantinib showed promising antitumor activity among patients with previously treated metastatic clear cell renal cell carcinoma, according to data published in The Lancet Oncology.

Recent data show that adherence to subcutaneous immunotherapy is low, even when there were no out-of-pocket costs to patients.

In this edition, immunotherapy improves survival rates of infants with leukemia; extreme poverty linked to higher risk for relapse among children with ALL; FDA approves allogeneic cell therapy and more.

Cancers with high vs. low tumor mutational burden appeared significantly associated with improved clinical outcomes among patients treated with immune checkpoint inhibitors, according to data published in JAMA Network Open.

Today is Melanoma Monday.

The addition of blinatumomab to Interfant-06 chemotherapy appeared safe for infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia, according to data published in The New England Journal of Medicine.

Only about one-third of patients adhered to their course of maintenance doses in their subcutaneous immunotherapy even when there were no out-of-pocket expenses, according to a study published in Annals of Allergy, Asthma & Immunology.